Watson Launches Omeprazole Delayed-Release Capsules, 40MG
July 25 2008 - 8:00AM
PR Newswire (US)
- 180-Days of Marketing Exclusivity Begins - CORONA, Calif., July
25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc.
(NYSE:WPI), a leading specialty pharmaceutical company, announced
today that its subsidiary has commenced commercial shipment of its
Omeprazole Delayed-Release Capsules USP product in the 40mg
strength from its Davie, Florida manufacturing facility. In
conjunction with the launch, Watson has 180 days of marketing
exclusivity for being the first to file an ANDA containing a
paragraph IV certification for the 40mg strength. Omeprazole is the
generic equivalent to AstraZeneca's Prilosec(R) Delayed-Release
Capsules USP and is indicated for the short-term treatment of
active duodenal ulcer. For the 12-months ending March 2008,
Prilosec(R) Delayed-Release Capsules and its generic equivalents
had total U.S. sales of approximately $200 million, according to
IMS Health. About Watson Pharmaceuticals, Inc. Watson
Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading
specialty pharmaceutical company that develops, manufactures,
markets, sells and distributes brand and generic pharmaceutical
products. Watson pursues a growth strategy combining internal
product development, strategic alliances and collaborations and
synergistic acquisitions of products and businesses. For press
releases and other company information, visit Watson
Pharmaceuticals' Web site at http://www.watson.com/.
Forward-Looking Statement Any statements contained in this press
release that refer to future events or other non-historical facts
are forward-looking statements that reflect Watson's current
perspective of existing trends and information as of the date of
this release. Except as expressly required by law, Watson disclaims
any intent or obligation to update these forward-looking
statements. Actual results may differ materially from Watson's
current expectations depending upon a number of factors affecting
Watson's business. These factors include, among others, the impact
of competitive products and pricing; market acceptance of and
continued demand for Watson's products; and other risks and
uncertainties detailed in Watson's periodic public filings with the
Securities and Exchange Commission, including but not limited to
Watson's Annual Report on Form 10-K for the year ended December 31,
2007. Prilosec(R) is a registered trademark of the AstraZeneca
group of companies. (Logo:
http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)
http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO
http://photoarchive.ap.org/ DATASOURCE: Watson Pharmaceuticals,
Inc. CONTACT: Patty Eisenhaur of Watson Pharmaceuticals, Inc.,
+1-951-493-5611 Web site: http://www.watson.com/
Copyright
Watson (NYSE:WPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Watson (NYSE:WPI)
Historical Stock Chart
From Apr 2023 to Apr 2024